🔴 Achieve Life Sciences is trading 5% down

Achieve Life Sciences is trading at $6.87, down 5.11%, with no confirmed October 5 company-specific catalyst.

• Recent coverage centers on Benjamin Halladay becoming CFO effective October 5, a previously announced transition; cytisinicline data presentation is planned for October 18–21, not a new negative development.
• The FDA’s earlier refusal to approve cytisinicline was reported in June; Q4 resubmission is planned, not a new October 5 event.
• Broader indices are mixed and do not clearly explain the stock-specific drop.